GRACEcast
Expert oncologists provide brief, distilled summaries of the most central issues in cancer management and emerging approaches for patients and caregivers. The Global Resource for Advancing Cancer Education (GRACE) is committed to providing the knowledge that will help enable the general public to be informed participants in their own care. Visit cancerGRACE.org for more info.

Drs. Nate Pennell, Mary Pinder, and Jack West discuss an encouraging study of dabrafenib, a BRAF inhibitor, for the limited number of NSCLC patients with a BRAF V600E mutation.


Dr. Mary Pinder of Moffitt Cancer Center reviews the CUSTOM trial, in which the study of molecular markers was expanded to patients with small cell lung cancer and thymic carcinomas.


Dr. David Spigel gives his view on more widespread availability of new mutation tests, provides his perspective on the likelihood that molecular oncology principles and targeted therapies will become more broadly applicable for other lung cancer subtypes.


Dr. Heather Wakelee, from Stanford University, describes which molecular markers she seeks for NSCLC patients.


Dr. Nate Pennell from Cleveland Clinic reviews the LUME Lung-1 trial presented by Reck at ASCO 2013, of Taxotere with or without nindetanib (BIBF-1120), an anti-angiogenic multikinase inhibitor, in advanced NSCLC.

Direct download: GRACEcastUC-139_Lung-Video_Nindetanib_BIBF1120_LUME_Lung-1.m4v
Category:Lung-Cancer-Video -- posted at: 4:09pm PST

Dr. Mary Pinder reviews promising studies from ASCO 2013 on second gen. ALK inhibitors LDK-378, CH5424802, and AP26113 in patients with ALK-positive advanced NSCLC, including impressive activity in crizotinib-refractory patients and those with brain mets.

Direct download: GRACEcastUC-137_Lung-Video_Second_Generation_ALK_Inhibitors.m4v
Category:Lung-Cancer-Video -- posted at: 4:09pm PST

Drs. Mary Pinder, Nate Pennell, and Jack West discuss promising work on immune checkpoint inhibitors such as MPPL-3280A, an anti-PDL1 immune-based therapy, and anti-PD1 therapy nivolumab, in advanced NSCLC.

Direct download: GRACEcastUC-136_Lung-Video_MPDL3280A_Spigel_ASCO_2013_NSCLC.m4v
Category:Lung-Cancer-Video -- posted at: 6:01pm PST

Drs. Mary Pinder, Nate Pennell, and Jack West discuss the results presented at ASCO 2013 of the GALAXY-1 trial of the HSP90 inhibitor ganetespib combined with Taxotere (docetaxel) as second line therapy for advanced NSCLC.

Direct download: GRACEcastUC-134_Lung-Video_GALAXY-1_Ganetespib_HSP90.m4v
Category:Lung-Cancer-Video -- posted at: 6:01pm PST

Dr. Larry Einhorn, Distinguished Professor of Medicine at Indiana Univ and former ASCO president, discusses the trend of patients consulting Dr.Google - finding information of varied quality on the internet.


Dr. Karen Kelly, of the University of California, Davis, gives her view on more widespread availability of new mutation tests.